Failure of Oral 4', 6-Dichloroflavan to Protect Against Rhinovirus Infection in Man

By
R. J. Phillpotts¹, J. Wallace¹, D. A. J. Tyrrell¹, D. S. Freestone², and W. M. Shepherd²

¹ MRC Common Cold Unit, Coombe Road, Salisbury, Wiltshire,
² Wellcome Research Laboratories, Langley Court, Beckenham, Kent, United Kingdom

With 1 Figure
Accepted September 20, 1982

Summary

4', 6-Dichloroflavan, a potent inhibitor of rhinovirus replication in vitro, was tested in a double-blind placebo controlled volunteer trial for its protective effect against experimental rhinovirus infection. Dichloroflavan was given orally (1 mg/kg, 3 times per day) for 3 doses before, and 13 doses after intranasal challenge with rhinovirus type 9, a type known to be highly sensitive in tissue culture. A total of 63 volunteers were included in the analysis for efficacy.

Dichloroflavan did not produce any consistent or significant reduction in quantitative clinical or laboratory evidence of infection, and there was no apparent negative correlation of such data with drug concentrations in plasma. It is concluded that administration of dichloroflavan in the oral formulation tested is not of value in the treatment of human rhinovirus infection.

Introduction

Colds are mild, self-limiting upper viral respiratory tract infections, the symptoms of which rarely last for more than a few days. However, because of the inconvenience caused to industry, education, and the individual, the common cold has long been considered a suitable goal for antiviral prophylaxis and therapy.

At least 50 per cent of colds are caused by rhinoviruses (5), which may also be responsible for relapses of chronic bronchitis (6) and the occurrence of wheezy bronchitis in children (4). The impracticability of prophylactic vaccination for rhinovirus infection, because of the large number of serotypes, has led to interest in the development of substances with activity against rhinoviruses. A number
of compounds have been synthesised, and evaluated in vitro and in vivo (9, 10). The results of rhinovirus challenge studies in man and apes using these compounds have proved disappointing, possibly because of their insufficient potency as inhibitors of rhinovirus replication.

Recently, two new and highly active compounds have been synthesised, 2-amino-1-(isopropyl sulphenyl)-6-benzimidazole phenyl ketone oxime (environoxime), and 4', 6-dichloroflavan (dichloroflavan). Concurrent intranasal and oral administration of environoxime has already been shown to reduce clinical symptoms and virus excretion in volunteers infected with a rhinovirus (8). Dichloroflavan (which appears to be the most potent inhibitor of rhinovirus replication yet described in the literature), is active against a sufficient number of rhinovirus serotypes to suggest that it may have clinical potential, and blood levels in excess of those required for virus inhibition are achieved after oral dosing in animals (1). Toxicological and pharmacological testing in animals, and some initial pharmacokinetic studies in man showed dichloroflavan to be extremely well tolerated. The lack of toxicity, combined with high antiviral activity and adequate absorption makes dichloroflavan one of the most promising candidate antirhinovirus compounds yet synthesised. We therefore undertook the following study in which oral dichloroflavan was tested in volunteers for its ability to protect against challenge with a virulent strain of rhinovirus type 9.

Materials and Methods

The study was approved by the Ethical Committee of Northwick Park Hospital, Harrow.

Volunteers

Healthy volunteers of both sexes, aged 18—50 years were recruited, screened for suitability, and housed in isolation at the Common Cold Unit according to our usual procedures (2). Volunteers known to be intolerant to maize oil or gelatin were excluded from the study. Initial blood samples were taken for routine haematological and biochemical tests including electrolytes and basic tests of hepatic and renal function, and to provide serum for determination of neutralising antibody to the challenge virus, rhinovirus type 9 (HRV9). Volunteers were allocated into two groups matched for age, sex and antibody titre to HRV9. One group was given dichloroflavan and the other placebo. Those with high antibody titres were challenged with saline, the rest were given nasal drops containing 10—20 TCID₅₀ of a virulent strain of rhinovirus type 9, propagated by intranasal passage in volunteers. Four days after virus challenge, and just prior to the penultimate dose of medication, a further blood sample was taken for haematology, biochemistry, and assay for dichloroflavan by gas chromatography-mass spectrometry.

The clinical effects were monitored by an observer unaware of the allocations of drug and virus. Each volunteer was assessed daily and assigned a daily score on the basis of clinical signs and symptoms. Colds were graded as nil, doubtful, very mild, mild, moderate or severe. Paper handkerchiefs used by volunteers were weighed in order to estimate daily nasal secretion. Nasal washings for virus isolation, titration and dichloroflavan assay were collected on the day before, and on days 2—6 after virus challenge. A further serum sample was requested from each volunteer 2 weeks after leaving the Unit, and titrated in parallel with the initial sample for neutralising antibody to HRV9. Volunteers were excluded from the trial if they developed signs of a cold before virus challenge, or were excluded retrospectively if wild rhinoviruses could be recovered from their prechallenge nasal washes.
**Dichloroflavan in Human Rhinovirus Infection**

**Medication**

Dichloroflavan was dissolved in maize oil and dispensed in soft gelatin capsules, each containing 10 mg drug in 0.25 ml maize oil. Placebo capsules contained maize oil alone and could not be differentiated from those containing drug. Capsules equivalent to 1 mg of drug/kg body weight were given under supervision 3 times per day at 8 hourly intervals. Volunteers were asked to chew the capsules, releasing their contents before swallowing. Three doses were given before, and 13 doses after virus challenge.

**Virological Procedures**

Nasal washes were collected in 10 ml of Hanks balanced salt solution, and aliquots stored at $-20^\circ C$ for dichloroflavan assay, or at $-70^\circ C$ after addition of an equal volume of nutrient broth. Aliquots stored at $-70^\circ C$ were tested for virus in human diploid foetal tonsil cells, and rhinovirus sensitive Ohio Hela cells; a fresh aliquot from each virus positive nasal wash was titrated by quantal assay in O-Hela cells. All cell cultures were incubated rolling at 33°C. At least one isolate from each volunteer was identified as HRV 9 by inhibition with a specific antiserum. Wild rhinoviruses isolated from pre-challenge nasal wash samples were identified by the characteristic pattern of cell destruction, and sensitivity to low pH.

Serum neutralising antibody titres to HRV 9 were estimated using a micro-method in O-HeLa cells. Sufficient virus was used in the screening test to give an easily recognisable CPE in controls within 48 hours. Paired serum samples were tested using a virus dose of 100 TCID$_{50}$. When cell destruction was complete in virus controls, microplates were fixed in 10 per cent formal saline and stained with 1 per cent alcoholic methyl violet. A 50 per cent reduction on colour was taken as the endpoint in each titration and a four fold or greater rise in antibody titre was considered significant.

**Statistical Analysis**

Differences in the frequency of colds, virus isolations and antibody rises were tested for significance using the Chi-squared test. Clinical score and nasal secretion weight data was evaluated using a non-parametric analysis of variance, in which each sample was divided into 3 strata according to pre-challenge serum neutralising antibody titre to HRV 9 ($< 1:2$, $1:2--1:8$, $> 1:8$) (7). Kendall’s rank correlation test was used to determine association, and the approximate statistical power of the trial was calculated assuming a log-normal distribution for each variable (11).

**Results**

Data from 63 volunteers were analysed. One volunteer given placebo was excluded because a rhinovirus was isolated from her pre-challenge nasal wash sample. One volunteer taking dichloroflavan developed a papular rash on her trunk. Medication was withdrawn three doses before completion of her course of treatment after which the rash disappeared. She was included in the analysis for efficacy. No other treatment related events were seen, and biochemical and haematological test values were unchanged by drug treatment. The mean concentration of dichloroflavan in plasma samples 8 hours after dosing was $14.25 \pm 11.81$ ng/ml; dichloroflavan could not be detected in nasal washes.

Thirteen volunteers were challenged with saline, 7 of whom were taking dichloroflavan, and 6 placebo. One volunteer on placebo developed a very mild cold, total clinical score 7.5, but virus could not be isolated from her nasal wash samples, nor a rise in serum neutralising antibody titre to HRV9 demonstrated, and her symptoms were thought to have been due to an unrelated cause.
Table 1. Summary of clinical and laboratory findings

| Group    | Pre-trial Ab titre | No. | Severe/moderate | Mild | V. Mild/absent |
|----------|--------------------|-----|-----------------|------|---------------|
| Placebo  | <2                 | 8   | 3               | 2    | 3             |
|          | 2–8                | 10  | 2               | 3    | 5             |
|          | >8                 | 5   | 0               | 0    | 5             |
| Total    | 23                 |     | 5 (22%)         | 5 (22%) | 13 (56%)      |
| 683      | <2                 | 13  | 5               | 2    | 6             |
|          | 2–8                | 9   | 0               | 1    | 8             |
|          | >8                 | 4   | 0               | 0    | 3             |
| Total    | 26                 |     | 5 (19%)         | 4 (15%) | 17 (65%)      |

Laboratory findings

| Group    | Pre-trial Ab titre | No. | Antibody rises | Virus isolated | Either or both |
|----------|--------------------|-----|----------------|----------------|----------------|
| Placebo  | <2                 | 8   | 4/7            | 5              | 5/7            |
|          | 2–8                | 10  | 8/9            | 8              | 8/9            |
|          | >8                 | 5   | 4              | 4              | 4              |
| Total    | 23                 |     | 16/21a (76%)   | 17 (74%)       | 17/21a (81%)   |
| 683      | <2                 | 13  | 7              | 12             | 12             |
|          | 2–8                | 9   | 6              | 8              | 8              |
|          | >8                 | 4   | 3              | 2              | 3              |
| Total    | 26                 |     | 16 (62%)       | 22 (85%)       | 23 (88%)       |

* 2 second serum samples not returned

The numbers of colds, their clinical grades, and the laboratory findings from 49 volunteers challenged with HRV9 are shown in Table 1. The numbers of volunteers in each prechallenge antibody category are similar in the dichloroflavan and placebo groups. Colds graded as mild, moderate or severe may be considered significant, as it is invariably possible to find laboratory evidence of infection with the challenge virus (either virus excretion, a rise in antibody titre, or both). There were fewer significant colds, and proportionally less four fold or greater rises in antibody titre in the dichloroflavan as compared to the placebo group. However, neither difference is statistically significant, and the trend is reversed when virus excretion, or overall laboratory evidence of infection are considered.

The dichloroflavan and placebo groups did not differ significantly in clinical scores, quantity of nasal secretion produced, or the amounts of virus recoverable from nasal wash on any day, nor did dichloroflavan produce a consistent reduction in any of these variables (Fig. 1). The drug and placebo groups were also compared by considering the total clinical score, mean daily weight of nasal secretion produced from the time of virus challenge to the end of the trial, and the mean titre of virus recoverable from nasal wash for each volunteer. No significant differences could be found (p values of 0.23, 0.37 and 0.60 respectively). We
were also unable to detect a negative correlation between any of these three variables, and plasma concentrations of dichloroflavan in those volunteers with laboratory evidence of infection (p = >0.1).

Calculation of the statistical power of this trial shows that we could have expected to detect reductions of approximately 77 per cent in clinical scores, 79 per cent in rhinorrhoea, and 82 per cent in virus excretion at the 5 per cent significance level, with 95 per cent confidence.

Discussion

Volunteer trials at the Common Cold Unit are conducted under carefully controlled conditions. Accurate clinical and laboratory data are obtained from all those taking part, and intercurrent infections with viruses other than the challenge virus are rigorously excluded by our quarantine and isolation procedure.

In the present study, 26 volunteers were given a maximum oral dose of dichloroflavan based on considerations of practicality and tolerance before and after challenge with a sensitive rhinovirus, type 9. One of these developed a papular rash, which may have been drug related, as symptoms disappeared after the withdrawal of medication. Otherwise dichloroflavan treatment seemed to be
completely without side-effects. Eight hours after an oral dose of 1 mg/kg, the mean plasma concentration of dichloroflavan was still more than 4 times the IC₅₀ for HRV9 as determined by plaque reduction assay (1), and the IC₅₀ for HRV9 was exceeded in the plasma of 25 of the 26 volunteers taking drug. Previous pharmacokinetic studies in human volunteers indicated that plasma concentrations well in excess of the IC₅₀ would have been present for most of the dosing period (3). However, when the quantitative clinical and laboratory data from volunteers taking dichloroflavan were compared with those from a placebo group, which had a similar susceptibility to the challenge virus, no beneficial effect of the drug could be demonstrated. Dichloroflavan could not be detected in respiratory secretions after oral dosing, which suggests that adequate concentrations of compound do not become available at the site of virus replication, the ciliated epithelium of the nose. However, the possibility that dichloroflavan might be present in inhibitory quantities in respiratory epithelial tissues but not be secreted remains. The failure of the drug to protect against challenge with rhinovirus type 9 makes this improbable.

A calculation of the statistical power of our trial showed that only large reductions in clinical score, rhinorrhoea, and virus excretion could be detected with any degree of certainty. Therefore, reproducible but lesser reductions in these variables could have been missed. However, in the conditions under which it was tested, dichloroflavan failed to produce a consistent reduction in any of the quantitative indices of rhinovirus infection. This finding, combined with the lack of a negative correlation between any of these quantitative indices and plasma concentrations of drug leads us to conclude that the formulation of dichloroflavan tested is of no value in the treatment of human rhinovirus infection. However, the effectiveness of other formulations and routes of administration remains to be tested. In particular, intranasal administration may prove effective.

Acknowledgments

The authors gratefully acknowledge the statistical help and advice of Christine Burke help from Dr. I. Caldwell in carrying out assays for dichloroflavan and the skilled assistance of members of staff at the Common Cold Unit, and the Wellcome Research Laboratories. We would also like to thank the volunteers for their help and co-operation.

References

1. Bauer, D. J., Selway, J. W. T., Batchelor, J. F., Tisdale, M., Caldwell, I. C., Young, D. A. B.: 4, 6, Dichloroflavan (BW 683) a new anti-rhinovirus compound. Nature 292, 369—370 (1981).
2. Beare, A. S., Reed, S. E.: The study of antiviral compounds in volunteers. In: Oxford, J. (ed.), Chemoprophylaxis and viral infections of the respiratory tract, 27—55. Cleveland: CRC Press 1977.
3. Fowler, A. S. E., Freestone, D. S.: Personal Communication.
4. Horn, M. E. C., Reed, S. E., Taylor, P.: Role of viruses and bacteria in acute wheezy bronchitis in childhood: a study of sputum. Arch. Dis. Childhood 54, 587—592 (1979).
5. Larson, H. E., Reed, S. E., Tyrrell, D. A. J.: Isolation of rhinoviruses and coronaviruses from 38 colds in adults. J. Med. Virol. 5, 221—229 (1980).
6. McHardy, V., Inglis, J. M., Calder, A., Crofton, J. W., Grigg, I., Ryland, D. A., Taylor, P., Chadwick, M., Coombs, B., Riddell, R. W.: A study of infective and other factors in exacerbations of chronic bronchitis. Brit. J. Dis. Chest. 74, 228–238 (1980).
7. Meddis, R.: Unified analysis of variance by ranks. Brit. J. Math. and Statist. Psych. 33, 84–98 (1980).
8. Phillpotts, R. J., Jones, R. W., DeLong, D. C., Reed, S. E., Wallace, J., Tyrrell, D. A. J.: The activity of enviroxime against rhinovirus infection in man. Lancet ii, 1342–1344 (1981).
9. Reed, S. E., Craig, J. W., Tyrrell, D. A. J.: Four compounds active against rhinovirus: Comparison in vitro and in volunteers. J. Infect. Dis. 133, A128–A135 (Suppl.) (1976).
10. Reed, S. E.: The assessment of antirhinoviral compounds with clinical potential. In: Collier, L. H., Oxford, J. (eds.), Developments in antiviral therapy. London: Academic Press 1980.
11. Snedecor, G. W., Cochran, W. G.: In: Statistical methods, 111–113. Publ. Iowa State University 1976.

Authors' address: Dr. R. J. Phillpotts, MRC Common Cold Unit, Harvard Hospital, Coombe Road, Salisbury, Wilts, SP2 8BW, United Kingdom.

Received July 2, 1982